Dlaczego nie należy przerywać terapii enzymami trzustkowymi w czasie pandemii COVID-19? Artykuł przeglądowy
##plugins.themes.bootstrap3.article.main##
Abstrakt
Diagnozowanie i skuteczne leczenie przewlekłego zapalenia trzustki wymaga współpracy pomiędzy lekarzem pierwszego kontaktu a specjalistą. W artykule podsumowano zasady leczenia niewydolności zewnątrzwydzielnicznej trzustki w przebiegu przewlekłego zapalenia trzustki w aspekcie aktualnej sytuacji epidemicznej.
##plugins.themes.bootstrap3.article.details##
Jak cytować
Lipiński , M. (2020). Dlaczego nie należy przerywać terapii enzymami trzustkowymi w czasie pandemii COVID-19?. Medycyna Faktów , 13(2(47), 208-212. https://doi.org/10.24292/01.MF.0220.10
Numer
Dział
Artykuły
Copyright © by Medical Education. All rights reserved.
Bibliografia
1. Dominguez-Muñoz JE. Diagnosis and treatment of pancreatic exocrine insufficiency. Curr Opin Gastroenterol. 2018; 34(5): 349‐54.
2. Kadaj-Lipka R, Lipiński M, Adrych K et al. Diagnostic and therapeutic recommendations for chronic pancreatitis. Recommendations of the Working Group of the Polish Society of Gastroenterology and the Polish Pancreas Club. Gastroenterology Rev. 2018; 13(3): 167-81.
3. Löhr JM, Dominguez-Munoz E, Rosendahl J et al. United European Gastroenterology evidence-based guidelines for the diagnosis and therapy of chronic pancreatitis (HaPanEU). United European Gastroenterol J. 2017; 5(2): 153-19.
4. Lipiński M, Rydzewska G. Zasady postępowania u pacjentów z przewlekłym zapaleniem trzustki i niewydolnością zewnątrzwydzielniczą trzustki w praktyce lekarza POZ. Lekarz POZ. 2018; 3: 199-203.
5. Whitcomb DC, Shimosegawa T, Chari ST et al. International consensus statements on early chronic Pancreatitis. Recommendations from the working group for the international consensus guidelines for chronic pancreatitis in collaboration with The International Association of Pancreatology, American Pancreatic Association, Japan Pancreas Society, PancreasFest Working Group and European Pancreatic Club. Pancreatology. 2018; pii: S1424-3903(18)30113-3.
6. Grant WB, Lahore H, McDonnell SL et al. Evidence that Vitamin D Supplementation Could Reduce Risk of Influenza and COVID-19 Infections and Deaths. Nutrients. 2020; 12(4): 988.
7. Li X, Xu S, Yu M et al. Risk factors for severity and mortality in adult COVID-19 inpatients in Wuhan [published online ahead of print, 2020 Apr 12]. J Allergy Clin Immunol. 2020; pii: S0091-6749(20)30495-4.
8. Wang K, Zhang Z, Yu M et al. 15-day mortality and associated risk factors for hospitalized patients with COVID-19 in Wuhan, China: an ambispective observational cohort study [published online ahead of print, 2020 Apr 23]. Intensive Care Med. 2020; 1‐3.
9. Wang T, Du Z, Zhu F et al. Comorbidities and multi-organ injuries in the treatment of COVID-19. Lancet. 2020; 395(10228): e52.
10. de la Iglesia-Garcia D, Vallejo-Senra N, Iglesias-Garcia J et al. Increased Risk of Mortality Associated With Pancreatic Exocrine Insufficiency in Patients With Chronic Pancreatitis. J Clin Gastroenterol. 2018; 52(8): e63‐e72.
11. de la Iglesia D, Vallejo-Senra N, López-López A et al. Pancreatic exocrine insufficiency and cardiovascular risk in patients with chronic pancreatitis: A prospective, longitudinal cohort study. J Gastroenterol Hepatol. 2019; 34(1): 277‐83.
12. Zhu L, She ZG, Cheng X et al. Association of Blood Glucose Control and Outcomes in Patients with COVID-19 and Pre-existing Type 2 Diabetes [published online ahead of print, 2020 May 1]. Cell Metab. 2020; pii: S1550-4131(20)30238-2.
13. Terzin V, Várkonyi T, Szabolcs A et al. Prevalence of exocrine pancreatic insufficiency in type 2 diabetes mellitus with poor glycemic control. Pancreatology. 2014; 14(5): 356‐60.
14. Rathmann W, Haastert B, Icks A et al. Low faecal elastase 1 concentrations in type 2 diabetes mellitus. Scand J Gastroenterol. 2001; 36(10): 1056‐61.
15. Larger E, Philippe MF, Barbot-Trystram L et al. Pancreatic exocrine function in patients with diabetes. Diabet Med. 2012; 29(8): 1047‐54.
16. Prasanna Kumar HR, Basavana Gowdappa H, Hosmani T et al. Exocrine Dysfunction Correlates with Endocrinal Impairment of Pancreas in Type 2 Diabetes Mellitus Indian. J Endocrinol Metab. 2018; 22(1): 121-5.
17. Jayawardena R, Sooriyaarachchi P, Chourdakis M et al. Enhancing immunity in viral infections, with special emphasis on COVID-19: A review [published online ahead of print, 2020 Apr 16]. Diabetes Metab Syndr. 2020; 14(4): 367‐82.
2. Kadaj-Lipka R, Lipiński M, Adrych K et al. Diagnostic and therapeutic recommendations for chronic pancreatitis. Recommendations of the Working Group of the Polish Society of Gastroenterology and the Polish Pancreas Club. Gastroenterology Rev. 2018; 13(3): 167-81.
3. Löhr JM, Dominguez-Munoz E, Rosendahl J et al. United European Gastroenterology evidence-based guidelines for the diagnosis and therapy of chronic pancreatitis (HaPanEU). United European Gastroenterol J. 2017; 5(2): 153-19.
4. Lipiński M, Rydzewska G. Zasady postępowania u pacjentów z przewlekłym zapaleniem trzustki i niewydolnością zewnątrzwydzielniczą trzustki w praktyce lekarza POZ. Lekarz POZ. 2018; 3: 199-203.
5. Whitcomb DC, Shimosegawa T, Chari ST et al. International consensus statements on early chronic Pancreatitis. Recommendations from the working group for the international consensus guidelines for chronic pancreatitis in collaboration with The International Association of Pancreatology, American Pancreatic Association, Japan Pancreas Society, PancreasFest Working Group and European Pancreatic Club. Pancreatology. 2018; pii: S1424-3903(18)30113-3.
6. Grant WB, Lahore H, McDonnell SL et al. Evidence that Vitamin D Supplementation Could Reduce Risk of Influenza and COVID-19 Infections and Deaths. Nutrients. 2020; 12(4): 988.
7. Li X, Xu S, Yu M et al. Risk factors for severity and mortality in adult COVID-19 inpatients in Wuhan [published online ahead of print, 2020 Apr 12]. J Allergy Clin Immunol. 2020; pii: S0091-6749(20)30495-4.
8. Wang K, Zhang Z, Yu M et al. 15-day mortality and associated risk factors for hospitalized patients with COVID-19 in Wuhan, China: an ambispective observational cohort study [published online ahead of print, 2020 Apr 23]. Intensive Care Med. 2020; 1‐3.
9. Wang T, Du Z, Zhu F et al. Comorbidities and multi-organ injuries in the treatment of COVID-19. Lancet. 2020; 395(10228): e52.
10. de la Iglesia-Garcia D, Vallejo-Senra N, Iglesias-Garcia J et al. Increased Risk of Mortality Associated With Pancreatic Exocrine Insufficiency in Patients With Chronic Pancreatitis. J Clin Gastroenterol. 2018; 52(8): e63‐e72.
11. de la Iglesia D, Vallejo-Senra N, López-López A et al. Pancreatic exocrine insufficiency and cardiovascular risk in patients with chronic pancreatitis: A prospective, longitudinal cohort study. J Gastroenterol Hepatol. 2019; 34(1): 277‐83.
12. Zhu L, She ZG, Cheng X et al. Association of Blood Glucose Control and Outcomes in Patients with COVID-19 and Pre-existing Type 2 Diabetes [published online ahead of print, 2020 May 1]. Cell Metab. 2020; pii: S1550-4131(20)30238-2.
13. Terzin V, Várkonyi T, Szabolcs A et al. Prevalence of exocrine pancreatic insufficiency in type 2 diabetes mellitus with poor glycemic control. Pancreatology. 2014; 14(5): 356‐60.
14. Rathmann W, Haastert B, Icks A et al. Low faecal elastase 1 concentrations in type 2 diabetes mellitus. Scand J Gastroenterol. 2001; 36(10): 1056‐61.
15. Larger E, Philippe MF, Barbot-Trystram L et al. Pancreatic exocrine function in patients with diabetes. Diabet Med. 2012; 29(8): 1047‐54.
16. Prasanna Kumar HR, Basavana Gowdappa H, Hosmani T et al. Exocrine Dysfunction Correlates with Endocrinal Impairment of Pancreas in Type 2 Diabetes Mellitus Indian. J Endocrinol Metab. 2018; 22(1): 121-5.
17. Jayawardena R, Sooriyaarachchi P, Chourdakis M et al. Enhancing immunity in viral infections, with special emphasis on COVID-19: A review [published online ahead of print, 2020 Apr 16]. Diabetes Metab Syndr. 2020; 14(4): 367‐82.